Switching to Deltoid Intramuscular Injections Maintains Therapeutic Trough Concentrations of Rilpivirine and Cabotegravir in People with HIV
Overview
Overview
Journal
Antimicrob Agents Chemother
Publisher
American Society for Microbiology
Specialty
Pharmacology
Date
2024 Mar 27
PMID
38534104
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Han K Antimicrob Agents Chemother. 2024; 68(5):e0020424.
PMID: 38534102 PMC: 11237482. DOI: 10.1128/aac.00204-24.
References
1.
Han K, Baker M, Lovern M, Paul P, Xiong Y, Patel P
. Population pharmacokinetics of cabotegravir following administration of oral tablet and long-acting intramuscular injection in adult HIV-1-infected and uninfected subjects. Br J Clin Pharmacol. 2022; 88(10):4607-4622.
PMC: 9543358.
DOI: 10.1111/bcp.15439.
View
2.
Margolis D, Gonzalez-Garcia J, Stellbrink H, Eron J, Yazdanpanah Y, Podzamczer D
. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017; 390(10101):1499-1510.
DOI: 10.1016/S0140-6736(17)31917-7.
View
3.
Spreen W, Ford S, Chen S, Wilfret D, Margolis D, Gould E
. GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects. J Acquir Immune Defic Syndr. 2014; 67(5):481-6.
DOI: 10.1097/QAI.0000000000000301.
View
4.
Orkin C, Arasteh K, Gorgolas Hernandez-Mora M, Pokrovsky V, Overton E, Girard P
. Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection. N Engl J Med. 2020; 382(12):1124-1135.
DOI: 10.1056/NEJMoa1909512.
View
5.
Landovitz R, Li S, Eron Jr J, Grinsztejn B, Dawood H, Liu A
. Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. Lancet HIV. 2020; 7(7):e472-e481.
PMC: 7859863.
DOI: 10.1016/S2352-3018(20)30106-5.
View